Kizaki, Hayato

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy 医薬品情報学講座 （Shiba-Kyoritsu）

Position

Research Associate/Assistant Professor/Instructor
Page Top ▲

Career 【 Display / hide 】

  • 2018.11
    -
    Present

    慶應義塾大学薬学部, 医薬品情報学講座, 助教

Page Top ▲

Academic Background 【 Display / hide 】

  • 2010.04
    -
    2014.03

    The University of Tokyo, 薬学部, 薬科学科

    University, Graduated

  • 2014.04
    -
    2016.03

    The University of Tokyo, 薬学系研究科, 薬科学専攻

    Graduate School, Completed, Master's course

  • 2016.09

    The University of Tokyo, 薬学系研究科, 薬科学専攻

    Graduate School, Doctoral course

  • 2017.09

    The University of Tokyo, 薬学系研究科, 薬学専攻

    Graduate School, Doctoral course

Page Top ▲

Academic Degrees 【 Display / hide 】

  • 薬科学（修士）, The University of Tokyo, Coursework, 2016.03

    黄色ブドウ球菌コロニースプレッディングにおけるPSM毒素の役割

Page Top ▲

Licenses and Qualifications 【 Display / hide 】

  • 東京大学フューチャーファカルティプログラム修了, 大学教員としてのキャリアを進むにあたり不可欠となる教育力の向上をめざすプログラム, 2017.03

  • 薬剤師免許, 2019

Page Top ▲
 

Research Areas 【 Display / hide 】

  • Life Science / Clinical pharmacy

  • Life Science / Medical management and medical sociology

Page Top ▲

Research Keywords 【 Display / hide 】

  • 介護施設

  • 医療安全

  • 医薬品情報

  • 多職種連携

  • 薬剤師

Page Top ▲
 

Papers 【 Display / hide 】

  • A cross-sectional survey of hepatitis B virus screening in patients who received immunosuppressive therapy for rheumatoid arthritis in Japan

    Yanagisawa Y., Imai S., Kizaki H., Hori S.

    Journal of Pharmaceutical Health Care and Sciences （Journal of Pharmaceutical Health Care and Sciences)  10 （ 1 ） 18 2024.12

    ISSN  2055-0294

    　View Summary

    Background: Patients with a history of hepatitis B virus (HBV) infection who are receiving immunosuppressive therapy are at risk of HBV reactivation and disease. Therefore, HBV screening is required prior to administering antirheumatic drugs with immunosuppressive effects. This study aimed to determine the status of hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), and hepatitis B surface antibody (HBsAb) screening prior to the initiation of drug therapy, including new antirheumatic drugs, in patients with rheumatoid arthritis. Methods: This retrospective cross-sectional study used data from April 2014 to August 2022 from the Japanese hospital-based administrative claims database. The inclusion criteria were rheumatoid arthritis and first prescription date of antirheumatic drugs. Results: A total of 82,282 patients with rheumatoid arthritis who were first prescribed antirheumatic drugs between April 2016 and August 2022 were included. Of the eligible patients, 9.7% (n=7,959) were screened for all HBV (HBsAg, HBsAb, and HbcAb) within 12 months prior to the date of initial prescription. The HBsAg test was performed in 30.0% (n=24,700), HBsAb test in 11.8% (n=9,717), and HBcAb test in 13.1% (n=10,824) of patients. The proportion of patients screened for HBV infection has been increasing since 2018; however, the proportion of patients screened for rheumatoid arthritis remains low. Conclusions: Our findings suggest that HBV screening may be insufficient in patients who received antirheumatic drugs. With the increasing use of new immunosuppressive antirheumatic drugs, including biological agents, healthcare providers should understand the risk of HBV reactivation and conduct appropriate screening.

  • External Validation and Update of the Risk Prediction Model for Denosumab-Induced Hypocalcemia Developed From a Hospital-Based Administrative Database.

    Ikegami K, Imai S, Yasumuro O, Tsuchiya M, Henmi N, Suzuki M, Hayashi K, Miura C, Abe H, Kizaki H, Funakoshi R, Sato Y, Hori S

    JCO clinical cancer informatics 8   e2400078 2024.07

  • Concomitant use of lansoprazole and ceftriaxone is associated with an increased risk of ventricular arrhythmias and cardiac arrest in a large Japanese hospital database.

    Mitsuboshi S, Imai S, Kizaki H, Hori S

    The Journal of infection （Journal of Infection)  89 （ 2 ） 106202 2024.06

    ISSN  0163-4453

    　View Summary

    Objectives: To determine whether concomitant use of ceftriaxone and oral or intravenous lansoprazole increases the risk of ventricular arrhythmia and cardiac arrest in the real-world setting in Japan. Methods: The data analyzed were obtained from the JMDC hospital-based administrative claims database for the period April 2014 to August 2022. Patients who received a proton pump inhibitor (PPI) while receiving ceftriaxone or sulbactam/ampicillin were identified. The frequency of ventricular arrhythmia and cardiac arrest was analyzed according to whether oral or intravenous PPI was concomitant with ceftriaxone or sulbactam/ampicillin. Estimates of the incidence of ventricular arrhythmia and cardiac arrest were then compared among the groups, using the Fine–Gray competing risk regression model. Results: The results showed that the risk of ventricular arrhythmia and cardiac arrest was significantly higher with concomitant ceftriaxone and oral lansoprazole (hazard ratio 4.57, 95% confidence interval 1.99–4.29, P < 0.01) or intravenous lansoprazole (hazard ratio 4.57, 95% confidence interval 1.24–16.80, P = 0.02) than with concomitant sulbactam/ampicillin and oral or intravenous lansoprazole. Conclusions: Oral and intravenous lansoprazole may increase the risk of ventricular arrhythmia and cardiac arrest in patients who are receiving ceftriaxone.

  • Medication incidents associated with the provision of medication assistance by non-medical care staff in residential care facilities.

    Kizaki H, Yamamoto D, Maki H, Masuko K, Konishi Y, Satoh H, Hori S, Sawada Y

    Drug discoveries & therapeutics 18 （ 1 ） 54 - 59 2024.03

    ISSN  1881-7831

  • Factor Analysis of Patients Who Find Tablets or Capsules Difficult to Swallow Due to Their Large Size: Using the Personal Health Record Infrastructure of Electronic Medication Notebooks

    Asano M., Imai S., Shimizu Y., Kizaki H., Ito Y., Tsuchiya M., Kuriyama R., Yoshida N., Shimada M., Sando T., Ishijima T., Hori S.

    Journal of Medical Internet Research （Journal of Medical Internet Research)  26 （ 1 ） e54645 2024.01

    ISSN  1439-4456

    　View Summary

    Background: Understanding patient preference regarding taking tablet or capsule formulations plays a pivotal role in treatment efficacy and adherence. Therefore, these preferences should be taken into account when designing formulations and prescriptions. Objective: This study investigates the factors affecting patient preference in patients who have difficulties swallowing large tablets or capsules and aims to identify appropriate sizes for tablets and capsules. Methods: A robust data set was developed based on a questionnaire survey conducted from December 1, 2022, to December 7, 2022, using the harmo smartphone app operated by harmo Co, Ltd. The data set included patient input regarding their tablet and capsule preferences, personal health records (including dispensing history), and drug formulation information (available from package inserts). Based on the medication formulation information, 6 indices were set for each of the tablets or capsules that were considered difficult to swallow owing to their large size and concomitant tablets or capsules (used as controls). Receiver operating characteristic (ROC) analysis was used to evaluate the performance of each index. The index demonstrating the highest area under the curve of the ROC was selected as the best index to determine the tablet or capsule size that leads to swallowing difficulties. From the generated ROCs, the point with the highest discriminative performance that maximized the Youden index was identified, and the optimal threshold for each index was calculated. Multivariate logistic regression analysis was performed to identify the risk factors contributing to difficulty in swallowing oversized tablets or capsules. Additionally, decision tree analysis was performed to estimate the combined risk from several factors, using risk factors that were significant in the multivariate logistic regression analysis. Results: This study analyzed 147 large tablets or capsules and 624 control tablets or capsules. The “long diameter + short diameter + thickness” index (with a 21.5 mm threshold) was identified as the best indicator for causing swallowing difficulties in patients. The multivariate logistic regression analysis (including 132 patients with swallowing difficulties and 1283 patients without) results identified the following contributory risk factors: aged <50 years (odds ratio [OR] 1.59, 95% CI 1.03-2.44), female (OR 2.54, 95% CI 1.70-3.78), dysphagia (OR 3.54, 95% CI 2.22-5.65), and taking large tablets or capsules (OR 9.74, 95% CI 5.19-18.29). The decision tree analysis results suggested an elevated risk of swallowing difficulties for patients with taking large tablets or capsules. Conclusions: This study identified the most appropriate index and threshold for indicating that a given tablet or capsule size will cause swallowing difficulties, as well as the contributory risk factors. Although some sampling biases (eg, only including smartphone users) may exist, our results can guide the design of patient-friendly formulations and prescriptions, promoting better medication adherence.

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

  • 新薬まるわかり アルツハイマー型認知症治療薬 アリドネパッチ 27.5mg/55mg （ドネペジル）

    木崎速人，名倉慎吾，佐藤宏樹，三木晶子著　堀 里子，澤田康文監.

    日経ドラッグインフォメーション ( 日経BP社)  315 2024.01

    Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media), Joint Work

  • 新薬まるわかり 骨粗鬆症治療薬 オスタバロ皮下注カートリッジ 1.5mg （アバロパラチド酢酸塩）

    木崎速人，名倉慎吾，佐藤宏樹，三木晶子著　堀 里子，澤田康文監.

    日経ドラッグインフォメーション ( 日経BP社)  313 2023.11

    Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media), Joint Work

  • 新薬まるわかり 抗リウマチ薬 メトジェクト皮下注 7.5mgシリンジ0.15mL/10mgシリンジ0.20mL/12.5mgシリンジ0.25mL/15mgシリンジ0.30mL （メトトレキサート）

    木崎速人，中田雄大，佐藤宏樹，三木晶子著　堀 里子，澤田康文監.

    日経ドラッグインフォメーション ( 日経BP社)  311 2023.11

    Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media), Joint Work

  • 腎細胞がん患者に対するチロシンキナーゼ阻害薬誘発性高血圧の発現に関する実態調査及び関連因子の検討

    中西 慧, 池上 慶祐, 今井 俊吾, 木崎 速人, 堀 里子

    医療情報学連合大会論文集 ((一社)日本医療情報学会)  43回   693 - 697 2023.11

    ISSN  1347-8508

  • 管理栄養士による地域薬局利用者の栄養サポートに向けた,住民の食生活の実態調査

    岡田 千乃, 中司 和希, 木崎 速人, 山田 真里, 安藤 湖乃, 衣笠 百合香, 徳村 百香, 加藤 芹奈, 山田 あすか, 中田 芽久美, 池田 裕樹, 宮本 興治, 今井 俊吾, 堀 里子

    New Diet Therapy ((一社)日本臨床栄養協会)  39 ( 2 ) 208 - 208 2023.09

    ISSN  0910-7258

display all >>

Page Top ▲

Presentations 【 Display / hide 】

  • 腎細胞がん患者に対するチロシンキナーゼ阻害薬誘発性高血圧 の発現に関する実態調査及び関連因子の検討

    中西慧，池上慶祐，今井俊吾， 木﨑速人，堀里子．

    第43回医療情報学連合大会, 

    2023.11
    , 

    Poster presentation

  • 正則化ロジスティック回帰/LightGBMを用いた服薬状況に対する服薬アドヒアランス素因の関連性解析及び重要度の検討

    飯野温，木﨑速人，今井俊吾，堀里子．

    2023.11
    , 

    Oral presentation (general)

  • External Validation and Update of the Risk Prediction Model of Denosumab-Induced Hypocalcemia Developed from Medical Big Data for Clinical Use.

    Keisuke Ikegami, Shungo Imai, Osamu Yasumuro, Masami Tsuchiya, Naomi Henmi, Mariko Suzuki, Katsuhisa Hayashi, Chisato Miura, Haruna Abe, Hayato Kizaki, Ryohkan Funakoshi, Yasunori Sato, Satoko Hori.

    FAPA 2023 (台湾) , 

    2023.10
    , 

    Poster presentation

  • 自然言語処理モデルBERTを用いた医薬品関連インシデント要因抽出のためのマルチラベル分類器の構築

    江原沙也加，木﨑速人，渡部哲，今井俊吾，矢田竣太郎，荒牧英治，安室修，舟越亮寛，堀里子．

    2023.09
    , 

    Poster presentation

  • 電子お薬手帳を基盤としたPHR活用による，「薬を大きくて飲みづらいと感じる」患者の予測モデル構築

    淺野 真輝，今井 俊吾，清水 友梨，木﨑 速人，吉田 奈央，島田 昌典，山東 崇紀，石島 知，堀 里子．

    医療薬学フォーラム2023/第31回クリニカルファーマシーシンポジウム, 

    2023.07
    , 

    Poster presentation

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • 要介護等高齢者の薬物治療適正化・医療安全確保に向けた介護施設における医薬品関連インシデント事例の要因解析

    2019.04
    -
    2020.03

    日本医薬品情報学会, 課題研究班, No Setting, Principal investigator

Page Top ▲

Awards 【 Display / hide 】

  • 第21介医薬品情報学会・学術大会　学生優秀発表ポスター賞

    木崎速人，佐藤宏樹，山本大輔，馬来秀行，益子幸太郎，小西ゆかり，浅井康平，堀里子，澤田康文, 2018.06, 医薬品情報学会, 介護士による服薬介助に伴い発生したインシデントに関する記述疫学的解析

    Type of Award： Award from Japanese society, conference, symposium, etc.

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • RESEARCH FOR BACHELOR'S THESIS 1

    2024

  • PRE-CLINICAL TRAINING FOR HOSPITAL & COMMUNITY PHARMACY

    2024

  • PHARMACEUTICAL-ENGLISH SEMINAR

    2024

  • INNOVATIONS IN DIGITAL HEALTH AND FUTURE HEALTHCARE

    2024

  • EVIDENCE-BASED MEDICINE

    2024

display all >>

Page Top ▲

Courses Previously Taught 【 Display / hide 】

  • 実務実習事前学習（実習）

    Keio University

    2018.04
    -
    2019.03
    , 

    Autumn Semester, Laboratory work/practical work/exercise, 160people

Page Top ▲

Educational Activities and Special Notes 【 Display / hide 】

  • 明治大学 「教職実践演習」：「教育実習の総まとめ」、授業題目：正しい薬の育て方

    2017.11

    , Special Affairs

  • 東京大学教養学部 全学自由研究ゼミナール「伝えるを学ぼう」：第6回「大学院生による模擬授業・検討・解説３」、授業題目：創る薬から育てる薬へ

    2017.05

    , Special Affairs

  • 学校法人河合塾 知の追究講座 講師：「薬の創り方・育て方〜薬学研究の最前線〜」

    2017.04

    , Special Affairs

  • 東京大学文学部 第1回留学生ワークショップ 講師：「何気ない日本人の習慣・考え方を学ぼう！」

    2017.03

    , Special Affairs

  • 学校法人河合塾 学びみらいプログラム 講師：「正しい薬の育て方」

    2017.03

    , Special Affairs

Page Top ▲
 

Memberships in Academic Societies 【 Display / hide 】

  • 日本薬学会, 

    2020
    -
    Present

  • 医薬品情報学会

    　

  • 医療薬学会

    　
Page Top ▲

Committee Experiences 【 Display / hide 】

  • 2020.04
    -
    Present

    研究企画委員会 委員, 一般財団法人　日本医薬品情報学会

Page Top ▲